Get the Stockscreener App
20.97
1.94%
0.40
After Hours:
20.30
-0.67
-3.20%
Structure Therapeutics Inc Adr stock is traded at $20.97, with a volume of 630.02K.
It is up +1.94% in the last 24 hours and down -16.69% over the past month.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.
See More
Previous Close:
$20.57
Open:
$20.5
24h Volume:
630.02K
Relative Volume:
0.68
Market Cap:
$1.26B
Revenue:
-
Net Income/Loss:
$-100.44M
P/E Ratio:
-9.4459
EPS:
-2.22
Net Cash Flow:
$-105.32M
1W Performance:
-3.94%
1M Performance:
-16.69%
6M Performance:
-33.39%
1Y Performance:
-56.83%
1-Day Range:
$20.42
$21.48
1-Week Range:
$20.42
$24.05
52-Week Range:
$13.22
$49.03
Structure Therapeutics Inc Adr Stock (GPCR) Company Profile
Name
Structure Therapeutics Inc Adr
Sector
Industry
Phone
(628) 229-9277
Address
611 GATEWAY BLVD SUITE 223, SOUTH SAN FRANCISCO
Compare GPCR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GPCR
Structure Therapeutics Inc Adr
|
20.97 | 1.26B | 0 | -100.44M | -105.32M | -2.22 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.99 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
508.86 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.71 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
540.71 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
254.09 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Structure Therapeutics Inc Adr Stock (GPCR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-02-25 | Initiated | Citigroup | Buy |
| Feb-28-25 | Initiated | William Blair | Outperform |
| Jan-08-25 | Initiated | Stifel | Buy |
| Dec-04-24 | Initiated | H.C. Wainwright | Buy |
| Sep-23-24 | Initiated | Morgan Stanley | Overweight |
| May-21-24 | Initiated | JP Morgan | Overweight |
| Apr-09-24 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-19-23 | Initiated | JMP Securities | Mkt Outperform |
| Jul-27-23 | Initiated | Piper Sandler | Overweight |
| May-25-23 | Resumed | Jefferies | Buy |
| Feb-28-23 | Initiated | BMO Capital Markets | Outperform |
| Feb-28-23 | Initiated | Guggenheim | Buy |
| Feb-28-23 | Initiated | Jefferies | Buy |
| Feb-28-23 | Initiated | SVB Securities | Outperform |
View All
Structure Therapeutics Inc Adr Stock (GPCR) Latest News
Data-Based Insights About Structure Therapeutics Inc ADR (GPCR) - Stocksregister
Oral Proteins & Peptides Market worth US$24.00 billion by 2030 with 22.1% CAGR | MarketsandMarkets™METRO - METRO - NEWS CHANNEL NEBRASKA
Cantor Fitzgerald Comments on GPCR FY2026 Earnings - Defense World
Oral Proteins & Peptides Market worth US$24.00 billion by 2030 with 22.1% CAGR | MarketsandMarketsNORTHEAST - NORTHEAST - NEWS CHANNEL NEBRASKA
Cantor Fitzgerald Estimates GPCR FY2025 Earnings - Defense World
Oral Proteins and Peptides Market Report Latest Trends and Future Opportunities Analysis - openPR.com
Structure Therapeutics Inc. (NASDAQ:GPCR) Given Average Recommendation of “Buy” by Brokerages - Defense World
Structure Therapeutics, Inc.: Catalyst-Rich Outlook and Strategic Preparations Support Buy Rating - TipRanks
Bank of America Corp DE Has $1.47 Million Position in Structure Therapeutics Inc. (NASDAQ:GPCR) - Defense World
GLP-1 Receptor Agonists: The Surge of M&A Activity and the Future of Metabolic Health - The National Law Review
Structure Therapeutics Set for Jefferies and Goldman Sachs Healthcare Conference Presentations in June - Stock Titan
Telomir Pharmaceuticals Confirms Telomir-1 Restores Vision and Retinal Structure in Age-Related Macular Degeneration (AMD) Animal Model Using FDA-Recognized Surrogate Endpoints - standard-journal.com
BNP Paribas Financial Markets Increases Stake in scPharmaceuticals Inc. (NASDAQ:SCPH) - Defense World
BNP Paribas Financial Markets Makes New $304,000 Investment in Structure Therapeutics Inc. (NASDAQ:GPCR) - Defense World
Analysts Have Conflicting Sentiments on These Healthcare Companies: Novo Nordisk (NVO), Beam Therapeutics (BEAM) and TScan Therapeutics (TCRX) - The Globe and Mail
Structure Therapeutics’ SWOT analysis: oral obesity drug stock poised for growth - Investing.com
Analysts Set Structure Therapeutics Inc. (NASDAQ:GPCR) Target Price at $78.00 - Defense World
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Relmada Therapeutics (RLMD) and Roivant Sciences (ROIV) - The Globe and Mail
Structure Therapeutics (NASDAQ:GPCR) Price Target Lowered to $75.00 at HC Wainwright - Defense World
FY2025 Earnings Forecast for GPCR Issued By Leerink Partnrs - Defense World
Envestnet Asset Management Inc. Has $201,000 Stock Position in Structure Therapeutics Inc. (NASDAQ:GPCR) - Defense World
Tower Research Capital LLC TRC Acquires 3,549 Shares of Structure Therapeutics Inc. (NASDAQ:GPCR) - The AM Reporter
Structure Therapeutics Reports Increased Losses Amid Rising R&D Costs - TipRanks
Structure Therapeutics Reports First Quarter 2025 Financial Results and Recent Highlights - Stock Titan
Wells Fargo & Company MN Boosts Stock Position in Structure Therapeutics Inc. (NASDAQ:GPCR) - Defense World
Analyzing Ratios: Structure Therapeutics Inc ADR (GPCR)’s Financial Story Unveiled - DWinneX
Analysts Offer Insights on Healthcare Companies: Guardant Health (GH), AnaptysBio (ANAB) and Alignment Healthcare (ALHC) - The Globe and Mail
Structure Therapeutics Inc ADR (NASDAQ: GPCR) Is Up 1.57% So Far This Year: What Will Happen Next? - Stocksregister
Structure Therapeutics (NASDAQ:GPCR) Research Coverage Started at Citigroup - Defense World
Structure Therapeutics Inc ADR (GPCR) expanding its growth trajectory ahead - Sete News
Buy Recommendation for Structure Therapeutics: Promising Pipeline and Obesity Treatment Market Potential - TipRanks
Citi sets Structure Therapeutics stock Buy rating, $60 target By Investing.com - Investing.com India
Technical analysis of Stoke Therapeutics Inc (STOK) stock chart patterns - uspostnews.com
Terns Pharmaceuticals Inc (TERN) deserves deeper analysis - uspostnews.com
A stock that deserves closer examination: Structure Therapeutics Inc ADR (GPCR) - uspostnews.com
What is the investor’s view on LSB Industries, Inc (LXU)? - uspostnews.com
Geode Capital Management LLC Increases Holdings in Structure Therapeutics Inc. (NASDAQ:GPCR) - Defense World
Pfizer eyes smaller drugmakers after failure of obesity pill - medwatch.com
The Potential Rise in the Price of Structure Therapeutics Inc ADR (GPCR) following insiders activity - knoxdaily.com
A Guide To The Risks Of Investing In Jamf Holding Corp (JAMF) - knoxdaily.com
GPCR Stock: A Voyage Through Structure Therapeutics Inc ADR’s Finances - investchronicle.com
Recent Insider Activity Could Benefit Pacific Premier Bancorp, Inc (PPBI) - knoxdaily.com
Barclays PLC Increases Stock Holdings in Structure Therapeutics Inc. (NASDAQ:GPCR) - Defense World
24,530 Shares in Structure Therapeutics Inc. (NASDAQ:GPCR) Acquired by Mariner LLC - Defense World
Market Update: CytomX Therapeutics Inc (CTMX) Sees Negative Movement, Closing at 0.71 - DWinneX
Stock Market Recap: Barrick Gold Corp (GOLD) Concludes at 19.30, a 1.31 Surge/Decline - DWinneX
Market Resilience: ReShape Lifesciences Inc (RSLS) Finishes Weak at 0.36, Down -0.85 - DWinneX
Gaining Ground: Structure Therapeutics Inc ADR (GPCR) Closes Lower at 23.62, Down -0.51 - DWinneX
JPMorgan Chase & Co. Has $876,000 Stock Holdings in Structure Therapeutics Inc. (NASDAQ:GPCR) - Defense World
Structure Therapeutics Inc. (NASDAQ:GPCR) Shares Acquired by LPL Financial LLC - Defense World
LPL Financial LLC Has $341,000 Stock Holdings in AdvisorShares Dorsey Wright FSM All Cap World ETF (NASDAQ:DWAW) - American Banking and Market News
Structure Therapeutics Inc Adr Stock (GPCR) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):